Vice President, Pharmaceutical & Process Development

About Stoke: Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ Position Purpose: This role will define and advance the scientific and technical strategy for Stoke’s Pharmaceutical & Process Development organization, enabling the discovery, preclinical evaluation, and technical development of transformative medicines that address the underlying causes of severe disease. This leader will guide multidisciplinary teams, external collaborators, strategic partners, and vendors to strengthen differentiated platform capabilities and translate scientific innovation into high-impact therapeutic opportunities. Working closely with leaders across preclinical research, data sciences, technical operations and clinical development, this individual will serve as a key driver of innovation, expanding the impact of Stoke’s gene regulation strategies and positioning the platform for sustained scientific and pipeline productivity. The successful candidate will bring deep, cross-disciplinary expertise across chemistry, biology, process and analytical sciences, formulation and delivery sciences, combined with the executive presence and organizational leadership required to build, inspire, and scale a high-performing R&D organization. Key Responsibilities: • Define and execute an enterprise-level strategic roadmap for oligonucleotide-based therapeutics, spanning nucleotide medicinal chemistry, process and analytical analytical sciences, delivery strategy, and formulation innovation • Advance platform innovation within an R&D environment to broaden the reach, differentiation, and therapeutic impact of oligonucleotides in regulating disease-relevant gene expression • Identify, assess, and integrate novel technologies that extend the impact of TANGO and other nucleic acid approaches by improving target presentation and engagement across disease-relevant tissues and cell types • Bring senior technical leadership and fluency across ASO, siRNA and PMO technologies, including chemistry, process and analytical sciences, delivery strategy, and formulation approaches • Build, lead, and scale high-performing scientific teams responsible for nucleic acid chemistries, bioconjugates, delivery systems, process development, analytical characterization, biological validation, and technical implementation • Apply scientific insight, strategic judgment, and disciplined governance to evaluate therapeutic concepts and platform technologies based on potential impact, differentiation, and product or technology risk • Partner with R&D and program leadership to shape early-stage therapeutic concepts, inform strategic direction and resourcing decisions, and support selection and advancement of pipeline candidates • Establish and steward external partnerships and collaborations that expand Stoke’s technologic capabilities in alignment with the organization’s mission and